Fuller & Thaler Asset Management Inc. Purchases 12,910 Shares of Hologic, Inc. $HOLX

Key Points

• Fuller & Thaler Asset Management Inc. increased its stake in Hologic, Inc. by 57.0% in Q1, holding 35,575 shares valued at approximately $2.20 million.
• Institutional investors now own 94.73% of Hologic's stock, with several firms like Quantbot Technologies LP and Dimensional Fund Advisors LP also significantly increasing their positions in the first quarter.
• Wall Street analysts have given Hologic an average rating of "Moderate Buy" with a target price of $78.00, reflecting optimism about the company's future performance and aligning with recent earnings reports that exceeded expectations.

Fuller & Thaler Asset Management Inc. boosted its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 57.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,575 shares of the medical equipment provider's stock after buying an additional 12,910 shares during the quarter. Fuller & Thaler Asset Management Inc.'s holdings in Hologic were worth $2,197,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the stock. Victory Capital Management Inc. boosted its stake in shares of Hologic by 34.4% during the first quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock valued at $408,283,000 after purchasing an additional 1,692,177 shares during the period. Invesco Ltd. boosted its stake in shares of Hologic by 18.8% during the first quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock valued at $298,655,000 after purchasing an additional 764,573 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of Hologic by 1.6% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider's stock valued at $276,303,000 after purchasing an additional 69,878 shares during the period. Northern Trust Corp boosted its stake in shares of Hologic by 26.9% during the fourth quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock valued at $226,898,000 after purchasing an additional 668,086 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Hologic by 8.1% during the first quarter. Dimensional Fund Advisors LP now owns 2,838,656 shares of the medical equipment provider's stock valued at $175,331,000 after purchasing an additional 213,366 shares during the period. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Stock Up 1.6%

Hologic stock traded up $1.09 during trading hours on Friday, hitting $68.26. 1,545,907 shares of the stock traded hands, compared to its average volume of 1,851,908. The firm's 50-day moving average price is $65.90 and its two-hundred day moving average price is $62.42. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The company has a market cap of $15.18 billion, a PE ratio of 28.32, a PEG ratio of 2.48 and a beta of 0.49. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm's quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Evercore ISI increased their price objective on Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Royal Bank Of Canada raised Hologic from a "sector perform" rating to an "outperform" rating and increased their price objective for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. Mizuho set a $75.00 price objective on Hologic in a research note on Thursday, July 31st. Citigroup upgraded Hologic from a "neutral" rating to a "buy" rating and upped their target price for the company from $60.00 to $80.00 in a report on Wednesday, July 9th. Finally, Argus upgraded Hologic from a "hold" rating to a "buy" rating and set a $80.00 target price for the company in a report on Monday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $78.00.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.